Search

Your search keyword '"Iacono, Lisa"' showing total 41 results
Start Over Author "Iacono, Lisa"
41 results on '"Iacono, Lisa"'

1. Data from The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development

Author

Goel, Sanjay, primary, Cohen, Marvin, primary, Çömezoglu, S. Nilgün, primary, Perrin, Lionel, primary, André, François, primary, Jayabalan, David, primary, Iacono, Lisa, primary, Comprelli, Adriana, primary, Ly, Van T., primary, Zhang, Donglu, primary, Xu, Carrie, primary, Humphreys, W. Griffith, primary, McDaid, Hayley, primary, Goldberg, Gary, primary, Horwitz, Susan B., primary, and Mani, Sridhar, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Data from Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

Author

Tolcher, Anthony W., primary, Sweeney, Christopher J., primary, Papadopoulos, Kyri, primary, Patnaik, Amita, primary, Chiorean, Elena G., primary, Mita, Alain C., primary, Sankhala, Kamalesh, primary, Furfine, Eric, primary, Gokemeijer, Jochem, primary, Iacono, Lisa, primary, Eaton, Cheryl, primary, Silver, Bruce A., primary, and Mita, Monica, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Data from The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development

Author

Goel, Sanjay, primary, Cohen, Marvin, primary, Çömezoglu, S. Nilgün, primary, Perrin, Lionel, primary, André, François, primary, Jayabalan, David, primary, Iacono, Lisa, primary, Comprelli, Adriana, primary, Ly, Van T., primary, Zhang, Donglu, primary, Xu, Carrie, primary, Humphreys, W. Griffith, primary, McDaid, Hayley, primary, Goldberg, Gary, primary, Horwitz, Susan B., primary, and Mani, Sridhar, primary

Published
2023
Full Text
View/download PDF

14. Novel function of the regulatory subunit of protein kinase A: regulation of cytochrome c oxidase activity and cytochrome c release

Author

Yang, Weng-Lang, Iacono, Lisa, Tang, Wei-Min, and Chin, Khew-Voon

Subjects
Enzymes -- Regulation, Cytochrome oxidase -- Research, Protein kinases -- Research, Biological sciences, Chemistry
Abstract

The regulatory subunit of protein kinase A (PKA) has been postulated to have other functions besides inhibiting the catalytic unit of the enzyme. Interaction cloning experiments were conducted to determine the other functions of the regulatory subunit of PKA. Fusion and coimmunoprecipitation were undertaken to produce combination proteins. Results reveal that the regulatory subunit of PKA also regulates cytochrome c oxidase.

Published
1998

26. Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β‐hydroxysteroid dehydrogenase type‐1 inhibitor BMS‐823778

Author

Cheng, Yaofeng, Wang, Lifei, Iacono, Lisa, Zhang, Donglu, Chen, Weiqi, Gong, Jiachang, Humphreys, William Griffith, and Gan, Jinping

Subjects
Adult, Male, Polymorphism, Genetic, Genotype, Pyridines, Triazoles, Hydroxylation, Drug Administration Schedule, Healthy Volunteers, Cytochrome P-450 CYP2C19, Renal Elimination, Young Adult, Glucuronides, Pharmacogenetics, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Hepatocytes, Microsomes, Liver, Humans, Oxidation-Reduction
Abstract

BMS-823778 is an inhibitor of 11β-hydroxysteroid dehydrogenase type-1, and thus a potential candidate for Type 2 diabetes treatment. Here, we investigated the metabolism and pharmacokinetics of BMS-823778 to understand its pharmacokinetic variations in early clinical trials.The metabolism of BMS-823778 was characterized in multiple in vitro assays. Pharmacokinetics were evaluated in healthy volunteers, prescreened as CYP2C19 extensive metabolizers (EM) or poor metabolizers (PM), with a single oral dose of [Three metabolites (5%) were identified in human hepatocytes and liver microsomes (HLM) incubations, including two hydroxylated metabolites (M1 and M2) and one glucuronide conjugate (M3). As the most abundant metabolite, M1 was formed mainly through CYP2C19. M1 formation was also correlated with CYP2C19 activities in genotyped HLM. In humans, urinary excretion of dosed radioactivity was significantly higher in EM (68.8%; 95% confidence interval 61.3%, 76.3%) than in PM (47.0%; 43.5%, 50.6%); only small portions (2%) were present in faeces or bile from both genotypes. In plasma, BMS-823778 exposure in PM was significantly (5.3-fold, P = 0.0097) higher than in EM. Furthermore, total radioactivity exposure was significantly higher (P 0.01) than BMS-823778 exposure in all groups, indicating the presence of metabolites. M1 was the only metabolite observed in plasma, and much lower in PM. In urine, the amount of M1 and its oxidative metabolite in EM was 7-fold of that in PM, while more glucuronide conjugates of BMS-823778 and M1 were excreted in PM.CYP2C19 polymorphisms significantly impacted systemic exposure and metabolism pathways of BMS-823778 in humans.

Published
2017

30. Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

Author

Tolcher, Anthony W., primary, Sweeney, Christopher J., additional, Papadopoulos, Kyri, additional, Patnaik, Amita, additional, Chiorean, Elena G., additional, Mita, Alain C., additional, Sankhala, Kamalesh, additional, Furfine, Eric, additional, Gokemeijer, Jochem, additional, Iacono, Lisa, additional, Eaton, Cheryl, additional, Silver, Bruce A., additional, and Mita, Monica, additional

Published
2011
Full Text
View/download PDF

31. The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development

Author

Goel, Sanjay, primary, Cohen, Marvin, additional, Çömezoglu, S. Nilgün, additional, Perrin, Lionel, additional, André, François, additional, Jayabalan, David, additional, Iacono, Lisa, additional, Comprelli, Adriana, additional, Ly, Van T., additional, Zhang, Donglu, additional, Xu, Carrie, additional, Humphreys, W. Griffith, additional, McDaid, Hayley, additional, Goldberg, Gary, additional, Horwitz, Susan B., additional, and Mani, Sridhar, additional

Published
2008
Full Text
View/download PDF

34. Temozolomide after Radiotherapy for Newly Diagnosed High-grade Glioma and Unfavorable Low-grade Glioma in Children

Author

Broniscer, Alberto, primary, Chintagumpala, Murali, additional, Fouladi, Maryam, additional, Krasin, Matthew J., additional, Kocak, Mehmet, additional, Bowers, Daniel C., additional, Iacono, Lisa C., additional, Merchant, Thomas E., additional, Stewart, Clinton F., additional, Houghton, Peter J., additional, Kun, Larry E., additional, Ledet, Davonna, additional, and Gajjar, Amar, additional

Published
2005
Full Text
View/download PDF

40. Computer Audit, Control, and Security.

Author

Iacono, Lisa M.

Subjects
Computer Audit, Control, and Security (Book), Books -- Book reviews
Abstract

Computer Audit, Control, and Security by Robert R. Moeller, John Wiley & Sons, Inc., One Wiley Drive, Somerset, New Jersey 08875, 1989, 592 pp. This book is designed for auditors [...]

Published
1990

41. The importance of pharmacokinetic limited sampling models for childhood cancer drug development.

Author

Panetta JC, Iacono LC, Adamson PC, and Stewart CF

Subjects
Child, Drug Industry trends, Drug Screening Assays, Antitumor, Humans, Models, Biological, Sample Size, Antineoplastic Agents pharmacokinetics, Drug Design, Neoplasms metabolism
Abstract

Since the development of effective chemotherapy for children with cancer, it has been recognized that the response of children to apparently identical therapy, both in terms of efficacy and toxicity, can vary widely. Our understanding of the interindividual differences in drug metabolism and disposition as significant determinants of drug response continues to evolve. An increasing area of clinical investigation is focused on studies to gain a better understanding of the variability in critical drug metabolic and elimination pathways and how this variability translates into varied pharmacological effects. Analyzing how drug metabolism and elimination are affected by patient characteristics such as age, sex, race, organ function, drug interactions, and, perhaps most importantly, genetic polymorphisms, is now a routine component of drug development studies. Recent advances in analytical methodologies, computer hardware, and pharmacokinetic software have improved our ability to conduct studies of the disposition of anticancer drugs in larger, more representative pediatric cancer populations. Along with advances in pharmacogenetics, the advances made in the conduct of pharmacokinetic studies in children with cancer have enabled establishment of sophisticated phenotype-genotype correlations, which may ultimately improve care. However, unique challenges and limitations remain that complicate the performance of pharmacokinetic studies in the child with cancer. This review addresses the need to perform pharmacokinetic studies throughout the drug development process in pediatric oncology patients, methods used to develop and validate limited sampling models, and selected examples of limited sampling models used in pharmacokinetic studies in children with cancer.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results